{
    "root": "308eeef2-80c3-1154-e063-6394a90a1088",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lamotrigine",
    "value": "20250317",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LAMOTRIGINE",
            "code": "U3H27498KS"
        }
    ],
    "indications": "lamotrigine indicated : epilepsy \u2014 adjunctive therapy patients aged 2 years older : partial-onset seizures . primary generalized tonic-clonic seizures . generalized seizures lennox-gastaut syndrome . ( 1.1 ) epilepsy\u2014monotherapy patients aged 16 years older : conversion monotherapy patients partial-onset seizures receiving treatment carbamazepine , phenytoin , phenobarbital , primidone , valproate single antiepileptic . ( 1.1 ) bipolar disorder : maintenance treatment bipolar disorder delay time occurrence mood episodes patients treated acute mood episodes standard therapy . ( 1.2 ) limitations : treatment acute manic mixed episodes recommended . effectiveness lamotrigine acute treatment mood episodes established .",
    "contraindications": "dosing based concomitant medications , indication , patient age . ( 2.1 , 2.2 , 2.3 , 2.4 ) avoid increased risk rash , recommended initial dose subsequent dose escalations exceeded . restart lamotrigine patients discontinued due rash unless potential benefits clearly outweigh risks . ( 2.1 , 5.1 ) adjustments maintenance doses necessary patients starting stopping estrogen-containing oral contraceptives . ( 2.1 , 5.9 ) discontinuation : taper period least 2 weeks ( approximately 50 % dose reduction per week ) . ( 2.1 , 5.10 ) epilepsy : adjunctive therapy\u2014see table 1 patients older 12 years tables 2 3 patients aged 2 12 years . ( 2.2 ) conversion monotherapy\u2014see table 4 . ( 2.3 ) bipolar disorder : tables 5 6 . ( 2.4 )",
    "warningsAndPrecautions": "lamotrigine tablets usp , 150 mg white off-white , round , flat , beveled-edged tablets bisect one side ; one side bisect debossed logo `` zc `` side debossed `` 81 `` side plain supplied follows : ndc : 70518-2535-00 packaging : 30 1 blister pack storage : store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] dry place . dispense tight , light-resistant container defined usp . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "hypersensitivity ingredients . ( boxed warning , 4 )",
    "indications_original": "Lamotrigine is indicated for: Epilepsy \u2014 adjunctive therapy in patients aged 2 years and older: Partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy\u2014monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine in the acute treatment of mood episodes has not been established.",
    "contraindications_original": "Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. Do not restart lamotrigine in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing oral contraceptives. ( 2.1 , 5.9 ) Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). ( 2.1 , 5.10 ) Epilepsy: Adjunctive therapy\u2014See Table 1 for patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12 years. ( 2.2 ) Conversion to monotherapy\u2014See Table 4. ( 2.3 ) Bipolar disorder: See Tables 5 and 6. ( 2.4 )",
    "warningsAndPrecautions_original": "Lamotrigine Tablets USP, 150 mg are white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of \"ZC\" and other side is debossed with \"81\" and other side is plain and are supplied as follows:\n                  NDC: 70518-2535-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Storage:\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [See USP Controlled Room Temperature] in a dry place.\n                  Dispense in a tight, light-resistant container as defined in the USP.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Hypersensitivity to the drug or its ingredients. ( Boxed Warning , 4 )"
}